BridgeMD
New treatment option for Diabetes Mellitus, Type 1
Official title A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
ClinicalTrials.gov ID: NCT07222137
What this study is testing
What is Baricitinib?
Baricitinib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for diabetes mellitus, type 1.
Also referred to as LY3009104.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 35
You may be able to join if
- Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related...
- Have Stage 1b or Stage 2 type 1 diabetes
- Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
You likely can't join if
- Have any other type of diabetes
- Have uncontrolled high blood pressure
- Have had a heart attack, heart disease, stroke, or heart failure
- Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Have a current or recent clinically serious infection
The study team makes the final eligibility decision.
Where it's taking place
- Tallahassee, Florida, United States
- Tampa, Florida, United States
- Iowa City, Iowa, United States
- West Des Moines, Iowa, United States
- Louisville, Kentucky, United States
- Philadelphia, Pennsylvania, United States
- Charlottesville, Virginia, United States
- Adelaide, Australia
- Box Hill, Australia
- Brisbane, Australia
- Melbourne, Australia
- Parkville, Australia
- Perth, Australia
- Randwick, Australia
- Westmead, Australia
- Brussels, Belgium
- Edegem, Belgium
- Leuven, Belgium
- Namur, Belgium
- Belo Horizonte, Brazil
+ 72 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tallahassee, Florida, United States; Tampa, Florida, United States; Iowa City, Iowa, United States; West Des Moines, Iowa, United States; Louisville, Kentucky, United States; Philadelphia, Pennsylvania, United States and 86 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.